AKT2 and ovarian carcinoma: However, AKT2 has also been linked to the maintenance of a Cisplatin resistant phenotype of ovarian carcinomas: it was shown that AKT2 inhibition re-sensitized Cisplatin resistant ovarian cancer cells [84].